April 23, 2021 -- Aptorum has entered into a material transfer and option agreement with Yale University to evaluate a group of preclinical stage novel immunomodulators.
The novel immunomodulators may potentially target autoimmune and oncology diseases, including rheumatoid arthritis, lupus, and sclerosis, as well as a variety of cancers. Aptorum also obtained an exclusive option to in-license the novel immunomodulators and its affiliated intellectual property rights including its patent rights and know-how.
Under the arrangement, Aptorum will be responsible for assessing Yale's novel immunomodulators against lupus, arthritis, inflammatory bowel diseases, neurodegenerative diseases, and other oncology indications. Upon exercising its option to license, Aptorum will work to develop and commercialize one or more of these novel immunomodulators, as supported by Yale.
Financial terms of the agreement were not disclosed.
Copyright © 2021 scienceboard.net